Ferrara R, Naigeon M, Auclin E, Duchemann B, Cassard L, Jouniaux JM, Boselli L, Grivel J, Desnoyer A, Mezquita L, Texier M, Caramella C, Hendriks L, Planchard D, Remon J, Sangaletti S, Proto C, Garassino MC, Soria JC, Marabelle A, Voisin AL, Farhane S, Besse B, Chaput N.
Clin Cancer Res. 2021 Jan 15;27(2):492-503. doi: 10.1158/1078-0432.CCR-20-1420. Epub 2020 Sep 4.
The objective of this project is to understand the potential common and opposing mechanisms leading to T cell senescence and the means to control it in autoimmunity, cancer and chronic viral infections.
In this context, Pr. Franck Carbonnel suggested exploring Crohn's disease as part of this project.
Pr. Mariette noted that this collaborative work perfectly embodies the spirit of the FHU CARE, which aims to create synergies between teams.
Outline of the clinical trial
Our first results?
Pr. Chaput and Dr. Nocturne present a collaborative project to explore lymphocyte senescence and its implication in autoimmune diseases and cancer.
Pr. Chaput's team has demonstrated the presence of senescent CD8+ T cells in lung cancer patients and high levels of these cells would be associated with resistance to anti-PD-(L)1 antibody. In addition to the physiological immune aging with age, senescent T cells can accumulate following chronic antigenic stimulation (cancer, autoimmune diseases) or in inflammatory diseases such as diabetes.
The objective of TNFSEN is to study T cell senescence in autoimmune diseases (rheumatoid arthritis, ankylosing spondylitis and Sjögren's syndrome) and its evolution during anti-TNF-α treatment. This study will allow to investigate common or opposite mechanisms leading to senescence, in cancer and autoimmune diseases.
In this context, Pr. Franck Carbonnel (link suggested exploring Crohn's disease. This collaborative work perfectly embodies the spirit of the FHU, which aims to create synergies between teams.
- Cette senescence est principalement drivée par les IFNs
- Pas de lien avec l’activité de la maladie
- Augmentation SIP dans les MAI (Sjo, PR, SpA)
To summarize TNFSEN:
- SIP ds MAI
> HV
> Cancer - Pas de lien avec activité maladie
- Pas de modulation sous anti-TNF
- Association avec IP-10
